AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 MAR 3 - (NewsRx.com & NewsRx.net) -- GTC Biotherapeutics, Inc., (GTCB) is restructuring its organization to support its focus on clinical development and commercialization of its internal pipeline of proprietary products and its portfolio of external programs.
GTC's internal pipeline of products includes ATryn, recombinant human serum albumin, and the MSP-1 malaria vaccine.
Under the restructuring plan, GTC is reducing its headcount approximately 20% from 159 to 127 full-time equivalent employees. With the restructuring, GTC plans to use approximately $20 million of cash in 2004 as it participates in the regulatory review of ATryn and further develops its other commercial programs. A restructuring charge of approximately $950,000 will be recorded in the first quarter of 2004.
"The restructuring that we are announcing ... is designed to support our strategic position as a commercial products company and to support the regulatory review process for ATryn," stated Geoffrey F. Cox, PhD, GTC's chairman of the board and CEO. "In addition to conserving cash during the regulatory review process for ATryn, this restructuring provides us with the flexibility to consider the strategic option of adding a small sales force in Europe for commercialization in the hereditary antithrombin deficiency ...
Source: HighBeam Research, Company restructures to support commercialization programs.